Ammar D, Sanges C, Henderson D, Schapitz I, Hudecek M, Luu M, Schüssler-Lenz M, Buchholz C, Franz P, Reiche K, Köhl U, Ifrah N, Quesnel B, Thermeli M, Kersten MJ, Locatelli F, D'Amore ML, Bonini C, Casucci M, Philippar U, Doeswijk R, Thielen F, Uyl-de Groot C, Theelen J, Schröder B, Kremer A, Quaranta M, Prosper F, Van den Brulle J, Grawunder U, Donnadieu E, Galy A, Ferrand C, Worel N, Busch D, Briones J, Sellner L, Kuball J, Sureda A, Awigena-Cook J

Cytotherapy. 2025 09 23;:101984

Harmonisation of quality control tests for academic production of CAR-T cells: a position paper from the WP-bioproduction of the UNITC consortium.

Marton C, Clémenceau B, Dachy G, Demerle C, Derenne S, Ferrand C, Giverne C, Latouche JB, Lemée L, Martinet J, Bonig H, Bensoussan D, Chabannon C, Köhl U, Deschamps M, De Vos J, Diana JS, Dougé A, Forcade E, Galaine J, Thiant S, Galy A, Larghero J, Reppel L, Viel S, Boyer O, Yakoub-Agha I

Bone Marrow Transplant. 2025 05 29;:

Identification of the conditions and minimum requirements necessary for the release of autologous fresh CAR T-cell products under hospital exemption: a position paper from the WP-bioproduction of the UNITC consortium.

Boyer O, Bensoussan D, Bönig H, Chabannon C, Clémenceau B, Cuffel A, Dachy G, de Vos J, Derenne S, Diana JS, Dougé A, Deramoudt L, Ferrand C, Forcade E, Galaine J, Galy A, Giverne C, Martinet J, Marton C, Larghero J, Reppel L, Viel S, Yakoub-Agha I, Deschamps M

Bone Marrow Transplant. 2025 01 25;:

RapaCaspase-9-based suicide gene applied to the safety of IL-1RAP CAR-T cells.

Bouquet L, Bôle-Richard E, Warda W, Neto Da Rocha M, Trad R, Nicod C, Haderbache R, Genin D, Ferrand C, Deschamps M

Gene Ther. 2023 05 12;:

CAR-T cells targeting IL-1RAP produced in a closed semiautomatic system are ready for the first phase I clinical investigation in humans.

Nicod C, da Rocha MN, Warda W, Roussel X, Haderbache R, Seffar E, Trad R, Bouquet L, Goncalves M, Bosdure L, Laude MC, Guiot M, Ferrand C, Deschamps M

Curr Res Transl Med. 2023 02 4;71(2):103385

Coated recombinant target protein helps explore IL-1RAP CAR T-cell functionality in vitro.

Da Rocha MN, Guiot M, Nicod C, Trad R, Bouquet L, Haderbache R, Warda W, Baurand PE, Jouanneau C, Dulieu P, Deschamps M, Ferrand C

Immunol Res. 2022 12 2;:

IL-1RAP, a Key Therapeutic Target in Cancer.

Frenay J, Bellaye PS, Oudot A, Helbling A, Petitot C, Ferrand C, Collin B, Dias AMM

Int J Mol Sci. 2022 11 29;23(23):

Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia.

Trad R, Warda W, Alcazer V, Neto da Rocha M, Berceanu A, Nicod C, Haderbache R, Roussel X, Desbrosses Y, Daguindau E, Renosi F, Roumier C, Bouquet L, Biichle S, Guiot M, Seffar E, Caillot D, Depil S, Robinet E, Salma Y, Deconinck E, Deschamps M, Ferrand C

J Immunother Cancer. 2022 07;10(7):

Kidney Transplant T-Cell-Mediated Rejection Occurring After Anti-CD19 CAR T-Cell Therapy for Refractory Aggressive Burkitt-like Lymphoma With 11q Aberration: A Case Report.

de Nattes T, Camus V, François A, Dallet G, Ferrand C, Guerrot D, Lemoine M, Morin F, Thieblemont C, Veresezan EL, Candon S, Latouche JB, Bertrand D

Am J Kidney Dis. 2021 Aug 27;:

Lymphoblastic T Cells and Mature NK Cells With the Same TCRγ Rearrangement: A Common Origin?

Roggy A, Biichle S, Ferrand C, Renosi F, Larosa F, Deconinck E, Daguindeau E, Collonge Rame MA, Schillinger F, Seilles E, Garnache-Ottou F

Hemasphere. 2021 Aug;5(8):e608

[Immunomonitoring of patients treated with CAR-T cells for hematological malignancy: Guidelines from the CARTi group and the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

Rubio MT, Varlet P, Allain V, Ballot C, Cuffel A, Deschamps M, Ferrand C, Foguenne J, Forcade E, Huynh A, Guihot A, Latouche JB, Lemarie C, Martinroche G, Morin F, Nguyen S, Schmit K, Servais S, Simonetta F, Yakoub-Agha I, Caillat Zucman S

Bull Cancer. 2021 Jul 9;:

Droplet digital PCR allows vector copy number assessment and monitoring of experimental CAR T cells in murine xenograft models or approved CD19 CAR T cell-treated patients.

Haderbache R, Warda W, Hervouet E, da Rocha MN, Trad R, Allain V, Nicod C, Thieblemeont C, Boissel N, Varlet P, Agha IY, Bouquet L, Guiot M, Venet F, Sujobert P, Roussel X, Rouzaire PO, Caillot D, Casasnovas O, Bories JC, Bachy E, Caillat-Zucman S, Deschamps M, Ferrand C

J Transl Med. 2021 Jun 21;19(1):265

Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis.

Renosi F, Roggy A, Giguelay A, Soret L, Viailly PJ, Cheok M, Biichle S, Angelot-Delettre F, Asnafi V, Macintyre E, Geffroy S, Callanan M, Petrella T, Deconinck E, Daguindau E, Harrivel V, Bouyer S, Salaun V, Saussoy P, Feuillard J, Fuseau P, Saas P, Adotévi O, Jardin F, Ferrand C, Preudhomme C, Colinge J, Roumier C, Garnache-Ottou F

Blood Adv. 2021 Mar 9;5(5):1540-1551

Overcoming target epitope masking resistance that can occur on low-antigen-expresser AML blasts after IL-1RAP chimeric antigen receptor T cell therapy using the inducible caspase 9 suicide gene safety switch.

Warda W, Da Rocha MN, Trad R, Haderbache R, Salma Y, Bouquet L, Roussel X, Nicod C, Deschamps M, Ferrand C

Cancer Gene Ther. 2021 Jan 7;:

EZH2 and KDM6B Expressions Are Associated with Specific Epigenetic Signatures during EMT in Non Small Cell Lung Carcinomas.

Lachat C, Bruyère D, Etcheverry A, Aubry M, Mosser J, Warda W, Herfs M, Hendrick E, Ferrand C, Borg C, Delage-Mourroux R, Feugeas JP, Guittaut M, Hervouet E, Peixoto P

Cancers (Basel). 2020 Dec 5;12(12):

Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape.

Zalmaï L, Viailly PJ, Biichle S, Cheok M, Soret L, Angelot-Delettre F, Petrella T, Collonge-Rame MA, Seilles E, Geffroy S, Deconinck E, Daguindau E, Bouyer S, Dindinaud E, Baunin V, Le Garff-Tavernier M, Roos-Weil D, Wagner-Ballon O, Salaun V, Feuillard J, Brun S, Drenou B, Mayeur-Rousse C, Okamba P, Dorvaux V, Tichionni M, Rose J, Rubio MT, Jacob MC, Raggueneau V, Preudhomme C, Saas P, Ferrand C, Adotevi O, Roumier C, Jardin F, Garnache-Ottou F, Renosi F

Haematologica. 2020 Oct 13;Online ahead of print:

Engineered IL-10 variants elicit potent immunomodulatory effects at low ligand doses.

Gorby C, Sotolongo Bellón J, Wilmes S, Warda W, Pohler E, Fyfe PK, Cozzani A, Ferrand C, Walter MR, Mitra S, Piehler J, Moraga I

Sci Signal. 2020 Sep 15;13(649):

CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm.

Bôle-Richard E, Fredon M, Biichlé S, Anna F, Certoux JM, Renosi F, Tsé F, Molimard C, Valmary-Degano S, Jenvrin A, Warda W, Pallandre JR, Bonnefoy F, Poussard M, Deschamps M, Petrella T, Roumier C, Macintyre E, Féger F, Brissot E, Mohty M, HoWangYin KY, Langlade-Demoyen P, Loustau M, Caumartin J, Godet Y, Binda D, Pagadoy M, Deconinck E, Daguindau E, Saas P, Ferrand C, Angelot-Delettre F, Adotévi O, Garnache-Ottou F

Leukemia. 2020 Feb 28;:

Post-Essential Thrombocythemia Myelofibrosis and Multiple Isodicentric Y Chromosomes: A Unique Case among a Rare Association.

Dahlen E, Sarghi SI, Renosi F, Ferrand C, Collonge-Rame MA, Kuentz P

Cytogenet. Genome Res.. 2020 Feb 1;:

Acute Myeloid Leukemia: From Biology to Clinical Practices Through Development and Pre-Clinical Therapeutics.

Roussel X, Daguindau E, Berceanu A, Desbrosses Y, Warda W, Neto da Rocha M, Trad R, Deconinck E, Deschamps M, Ferrand C

Front Oncol. 2020 ;10:599933

How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?

Garnache-Ottou F, Vidal C, Biichlé S, Renosi F, Poret E, Pagadoy M, Desmarets M, Roggy A, Seilles E, Soret L, Schillinger F, Puyraimond S, Petrella T, Preudhomme C, Roumier C, MacIntyre EA, Harrivel V, Desbrosses Y, Gruson B, Geneviève F, Thepot S, Drebit Y, Leguay T, Gros FX, Lechevalier N, Saussoy P, Salaun V, Cornet E, Benseddik Z, Veyrat-Masson R, Wagner-Ballon O, Salanoubat C, Maynadié M, Guy J, Caillot D, Jacob MC, Cahn JY, Gressin R, Rose J, Quesnel B, Guerin E, Trimoreau F, Feuillard J, Gourin MP, Plesa A, Baseggio L, Arnoux I, Vey N, Blaise D, Lacroix R, Arnoulet C, Benet B, Dorvaux V, Bret C, Drenou B, Debliquis A, Latger-Cannard V, Bonmati C, Bene MC, Peterlin P, Ticchioni M, Rohrlich PS, Arnaud A, Wickenhauser S, Bardet V, Brechignac S, Papoular B, Raggueneau V, Vargaftig J, Letestu R, Lusina D, Braun T, Foissaud V, Tamburini J, Bennani H, Freynet N, Cordonnier C, Le Garff-Tavernier M, Jacques N, Maloum K, Roos-Weil D, Bouscary D, Asnafi V, Lhermitte L, Suarez F, Lengline E, Féger F, Battipaglia G, Mohty M, Bouyer S, Ghoual O, Dindinaud E, Basle C, Puyade M, Lafon C, Fest T, Roussel M, Cahu X, Bera E, Daliphard S, Jardin F, Campos L, Solly F, Guyotat D, Galoisy AC, Eischen A, Mayeur-Rousse C, Guffroy B, Recher C, Loosveld M, Garnier A, Barlogis V, Rosenthal MA, Brun S, Contentin N, Maury S, Callanan M, Lefebvre C, Maillard N, Okamba P, Ferrand C, Adotevi O, Saas P, Angelot-Delettre F, Binda D, Deconinck E

Blood Adv. 2019 Dec 23;3(24):4238-4251

[Requirements for academic production of CAR-T cells in accordance with Good Pharmaceutical Practice (GMP). Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

Deschamps M, Decot V, Giverne C, Pinturaud M, Vaissié A, Parquet N, Olivero S, Anne-Claire M, Bay JO, Yakoub-Agha I, Ferrand C

Bull Cancer. 2019 Sep 20;:

Altered thymic CD4 T-cell recovery after allogeneic hematopoietic stem cell transplantation is critical for nocardiosis.

Roussel X, Daguindau E, Berceanu A, Desbrosses Y, Saas P, Ferrand C, Seilles E, Pouthier F, Deconinck E, Larosa F

Curr Res Transl Med. 2019 Jun 1;:

CML hematopoietic stem cells expressing IL-1RAP can be targeted by chimeric antigen receptor (CAR)-engineered T cells.

Warda W, Larosa F, Neto Da Rocha M, Trad R, Deconinck E, Fajloun Z, Faure C, Caillot D, Moldovan M, Valmary-Degano S, Biichle S, Daguindau E, Garnache-Ottou F, Tabruyn S, Adotévi O, Deschamps M, Ferrand C

Cancer Res.. 2018 Dec 4;:

Uraemia-induced immune senescence and clinical outcomes in chronic kidney disease patients.

Crépin T, Legendre M, Carron C, Vachey C, Courivaud C, Rebibou JM, Ferrand C, Laheurte C, Vauchy C, Gaiffe E, Saas P, Ducloux D, Bamoulid J

Nephrol. Dial. Transplant.. 2018 Sep 6;:

Isolation and characterization of an HLA-DRB1*04-restricted HPV16-E7 T cell receptor for cancer immunotherapy.

Mercier-Letondal P, Marton C, Deschamps M, Ferrand C, Vauchy C, Chenut C, Baguet A, Adotévi O, Borg C, Galaine J, Godet Y

Hum. Gene Ther.. 2018 Aug 23;:

In situ delivery of allogeneic natural killer cell (NK) combined with Cetuximab in liver metastases of gastrointestinal carcinoma: A phase I clinical trial.

Adotevi O, Godet Y, Galaine J, Lakkis Z, Idirene I, Certoux JM, Jary M, Loyon R, Laheurte C, Kim S, Dormoy A, Pouthier F, Barisien C, Fein F, Tiberghien P, Pivot X, Valmary-Degano S, Ferrand C, Morel P, Delabrousse E, Borg C

Oncoimmunology. 2018 ;7(5):e1424673

Potential added value of a RT-qPCR method of SOX 11 expression, in the context of a multidisciplinary diagnostic assessment of B cell malignancies.

Magne J, Jenvrin A, Chauchet A, Casasnovas O, Donzel A, Jego L, Aral B, Guy J, Nadal N, Vernerey D, Callier P, Garnache-Ottou F, Ferrand C

Exp Hematol Oncol. 2018 ;7:5

SALL4 oncogene is an immunogenic antigen presented in various HLA-DR contexts.

Kroemer M, Spehner L, Mercier-Letondal P, Boullerot L, Kim S, Jary M, Galaine J, Picard E, Ferrand C, Nguyen T, Larosa F, Adotévi O, Godet Y, Borg C

Oncoimmunology. 2018 ;7(4):e1412030

New advances in DPYD genotype and risk of severe toxicity under capecitabine.

Etienne-Grimaldi MC, Boyer JC, Beroud C, Mbatchi L, van Kuilenburg A, Bobin-Dubigeon C, Thomas F, Chatelut E, Merlin JL, Pinguet F, Ferrand C, Meijer J, Evrard A, Llorca L, Romieu G, Follana P, Bachelot T, Chaigneau L, Pivot X, Dieras V, Largillier R, Mousseau M, Goncalves A, Roché H, Bonneterre J, Servent V, Dohollou N, Château Y, Chamorey E, Desvignes JP, Salgado D, Ferrero JM, Milano G

PLoS ONE. 2017 ;12(5):e0175998

Multimodal imaging of a humanized orthotopic model of hepatocellular carcinoma in immunodeficient mice.

Wu T, Heuillard E, Lindner V, Bou About G, Ignat M, Dillenseger JP, Anton N, Dalimier E, Gossé F, Fouré G, Blindauer F, Giraudeau C, El-Saghire H, Bouhadjar M, Calligaro C, Sorg T, Choquet P, Vandamme T, Ferrand C, Marescaux J, Baumert TF, Diana M, Pessaux P, Robinet E

Sci Rep. 2016 Oct;6:35230

Exposure to hypomethylating agent, 5-azacytidine, may improve iCasp9 suicide gene therapy for treating GvHD in allografts.

Bôle-Richard E, Gamonet C, Certoux JM, Idirene I, Larosa F, Deconinck E, Mosseley AM, Tiberghien P, Borg C, Ferrand C, Deschamps M

Gene Ther.. 2016 Aug;23(8-9):664-72

Involvement and prognosis value of CD8(+) T cells in giant cell arteritis.

Samson M, Ly KH, Tournier B, Janikashvili N, Trad M, Ciudad M, Gautheron A, Devilliers H, Quipourt V, Maurier F, Meaux-Ruault N, Magy-Bertrand N, Manckoundia P, Ornetti P, Maillefert JF, Besancenot JF, Ferrand C, Mesturoux L, Labrousse F, Fauchais AL, Saas P, Martin L, Audia S, Bonnotte B

J. Autoimmun.. 2016 Aug;72:73-83

IL-21-Induced MHC Class II+ NK Cells Promote the Expansion of Human Uncommitted CD4+ Central Memory T Cells in a Macrophage Migration Inhibitory Factor-Dependent Manner.

Loyon R, Picard E, Mauvais O, Queiroz L, Mougey V, Pallandre JR, Galaine J, Mercier-Letondal P, Kellerman G, Chaput N, Wijdenes J, Adotévi O, Ferrand C, Romero P, Godet Y, Borg C

J. Immunol.. 2016 Jul;197(1):85-96

Immunoprevalence and magnitude of HLA-DP4 versus HLA-DR-restricted spontaneous CD4(+) Th1 responses against telomerase in cancer patients.

Laheurte C, Galaine J, Beziaud L, Dosset M, Kerzerho J, Jacquemard C, Gaugler B, Ferrand C, Dormoy A, Aubin F, Jacoulet P, Westeel V, Borg C, Tartour E, Godet Y, Maillère B, Adotévi O

Oncoimmunology. 2016 May;5(5):e1137416

Suicide gene-modified killer cells as an allogeneic alternative to autologous cytokine-induced killer cell immunotherapy of hepatocellular carcinoma.

Wu T, Leboeuf C, Durand S, Su B, Deschamps M, Zhang X, Ferrand C, Pessaux P, Robinet E

Mol Med Rep. 2016 Mar;13(3):2645-54

The alternative CD20 transcript variant is not a surrogate marker for resistance to rituximab in patients with rheumatoid arthritis.

Gamonet C, Deschamps M, Marion S, Herbein G, Chiocchia G, Auger I, Saas P, Ferrand C, Toussirot E

Rheumatology (Oxford). 2015 Sep;54(9):1744-5

CD20 alternative splicing isoform generates immunogenic CD4 helper T epitopes.

Vauchy C, Gamonet C, Ferrand C, Daguindau E, Galaine J, Beziaud L, Chauchet A, Henry Dunand CJ, Deschamps M, Rohrlich PS, Borg C, Adotevi O, Godet Y

Int J Cancer. 2015 Jul 1;137(1):116-26

ATG-Induced Accelerated Immune Senescence: Clinical Implications in Renal Transplant Recipients.

Crepin T, Carron C, Roubiou C, Gaugler B, Gaiffe E, Simula-Faivre D, Ferrand C, Tiberghien P, Chalopin JM, Moulin B, Frimat L, Rieu P, Saas P, Ducloux D, Bamoulid J

Am J Transplant. 2015 Mar 10

Prevention of hepatitis C virus infection by adoptive allogeneic immunotherapy using suicide gene-modified lymphocytes: an in vitro proof-of-concept.

Leboeuf C, Roser-Schilder J, Lambotin M, Durand S, Wu T, Fauvelle C, Su B, Bole-Richard E, Deschamps M, Ferrand C, Tiberghien P, Pessaux P, Baumert TF, Robinet E

Gene Ther. 2015 Feb;22(2):172-80

Editorial: Improving the safety of cell therapy products by suicide gene transfer.

Bole-Richard E, Deschamps M, Ferrand C, Robinet E

Front Pharmacol. 2015 Aug 25;6:174

New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignancies.

Gamonet C, Bole-Richard E, Delherme A, Aubin F, Toussirot E, Garnache-Ottou F, Godet Y, Ysebaert L, Tournilhac O, Caroline D, Larosa F, Deconinck E, Saas P, Borg C, Deschamps M, Ferrand C

Exp Hematol Oncol. 2015 ;5:7

Minimal residual disease detection in cryopreserved ovarian tissue by multicolor flow cytometry in acute myeloid leukemia.

Zver T, Alvergnas-Vieille M, Garnache-Ottou F, Ferrand C, Roux C, Amiot C

Haematologica. 2014 Dec;99(12):e249-52

Constitutional and somatic deletions of the Williams-Beuren syndrome critical region in Non-Hodgkin inverted question marks Lymphoma.

Guenat D, Quentin S, Rizzari C, Lundin C, Coliva T, Edery P, Fryssira H, Bermont L, Ferrand C, Soulier J, Christophe B, Rohrlich PS

J Hematol Oncol. 2014 Nov 7;7(1):82.

Diagnosis and management of nocardiosis after bone marrow stem cell transplantation in adults: lack of lymphocyte recovery as a major contributing factor.

Mansi L, Daguindau E, Saas P, Pouthier F, Ferrand C, Dormoy A, Patry I, Garnache F, Rohrlich PS, Deconinck E, Larosa F

Pathol Biol (Paris). 2014 Jun;62(3):156-61

T-cell therapy using a bank of EBV-specific cytotoxic T cells: lessons from a phase I/II feasibility and safety study.

Gallot G, Vollant S, Saiagh S, Clemenceau B, Vivien R, Cerato E, Bignon JD, Ferrand C, Jaccard A, Vigouroux S, Choquet S, Dalle JH, Frachon I, Bruno B, Mothy M, Mechinaud F, Leblond V, Milpied N, Vie H

J Immunother. 2014 Apr;37(3):170-9

In vivo proof of concept of adoptive immunotherapy for hepatocellular carcinoma using allogeneic suicide gene-modified killer cells.

Leboeuf C, Mailly L, Wu T, Bour G, Durand S, Brignon N, Ferrand C, Borg C, Tiberghien P, Thimme R, Pessaux P, Marescaux J, Baumert TF, Robinet E

Mol Ther. 2014 Mar;22(3):634-44

Constitutional and somatic deletions of the Williams-Beuren syndrome critical region in non-Hodgkin lymphoma.

Guenat D, Quentin S, Rizzari C, Lundin C, Coliva T, Edery P, Fryssira H, Bermont L, Ferrand C, Soulier J, Borg C, Rohrlich PS

J Hematol Oncol. 2014 Nov 7;7:82

Lack of expression of an alternative CD20 transcript variant in circulating B cells from patients with pemphigus.

Gamonet C, Ferrand C, Colliou N, Musette P, Joly P, Girardin M, Humbert P, Aubin F

Exp Dermatol. 2014 Jan;23(1):66-7

Preferential splenic CD8(+) T-cell activation in rituximab-nonresponder patients with immune thrombocytopenia.

Audia S, Samson M, Mahevas M, Ferrand C, Trad M, Ciudad M, Gautheron A, Seaphanh F, Leguy V, Berthier S, Salles B, Martin L, Lorcerie B, Ortega-Deballon P, Facy O, Caillot D, Soudry-Faure A, Michel M, Godeau B, Larmonier N, Saas P, Janikashvili N, Bonnotte B

Blood. 2013 Oct 3;122(14):2477-86

Incidence and risk factors of anti-HLA immunization after pregnancy.

Masson E, Vidal C, Deschamps M, Bongain S, Thevenin C, Dupont I, Rietmulher D, Pouthier F, Mongaillard G, Chabod J, Ferrand C, Tiberghien P, Rebibou JM

Hum Immunol. 2013 Aug;74(8):946-51

Influence of fractalkine receptor gene polymorphisms V249I-T280M on cancer occurrence after renal transplantation.

Courivaud C, Bamoulid J, Loupy A, Deschamps M, Ferrand C, Simula-Faivre D, Tiberghien P, Chalopin JM, Legendre C, Thervet E, Borg C, Saas P, Ducloux D

Transplantation. 2013 Mar;95(5):728-32

A successful renal transplantation for renal failure after dasatinib-induced thrombotic thrombocytopenic purpura in a patient with imatinib-resistant chronic myelogenous leukaemia on nilotinib.

Martino S, Daguindau E, Ferrand C, Bamoulid J, Hayette S, Nicolini FE, Capellier G, Deconinck E, Larosa F

Leuk Res Rep. 2013 Mar 19;2(1):29-31

High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia.

Pasquet M, Bellanne-Chantelot C, Tavitian S, Prade N, Beaupain B, Larochelle O, Petit A, Rohrlich P, Ferrand C, Van Den Neste E, Poirel HA, Lamy T, Ouachee-Chardin M, Mansat-De Mas V, Corre J, Recher C, Plat G, Bachelerie F, Donadieu J, Delabesse E

Blood. 2013 Jan 31;121(5):822-9

Isolation of human CD4/CD8 double-positive, graft-versus-host disease-protective, minor histocompatibility antigen-specific regulatory T cells and of a novel HLA-DR7-restricted HY-specific CD4 clone.

Eljaafari A, Yuruker O, Ferrand C, Farre A, Addey C, Tartelin ML, Thomas X, Tiberghien P, Simpson E, Rigal D, Scott D

J Immunol. 2013 Jan 1;190(1):184-94

Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors.

Isambert N, Fumoleau P, Paul C, Ferrand C, Zanetta S, Bauer J, Ragot K, Lizard G, Jeannin JF, Bardou M

BMC Cancer. 2013 Apr 2;13:172

Intracytoplasmic detection of TCL1--but not ILT7-by flow cytometry is useful for blastic plasmacytoid dendritic cell leukemia diagnosis.

Angelot-Delettre F, Biichle S, Ferrand C, Seilles E, Gaugler B, Harrivel V, Rosenthal-Allieri MA, Deconinck E, Saas P, Garnache-Ottou F

Cytometry A. 2012 Aug;81(8):718-24

Autologous transplantation in CLL patients with B and C Binet stages: final results of the prospective randomized GOELAMS LLC 98 trial.

Brion A, Mahe B, Kolb B, Audhuy B, Colombat P, Maisonneuve H, Foussard C, Bureau A, Ferrand C, Lesesve JF, Bene MC, Feugier P

Bone Marrow Transplant. 2012 Apr;47(4):542-8

Systematic donor blood qualification by flow cytometry would have been able to avoid CLL-type MBL transmission after unrelated hematopoietic stem cell transplantation.

Ferrand C, Garnache-Ottou F, Collonge-Rame MA, Larosa F, Blanc M, Behar C, Giannoli C, Garnier F, Tiberghien P, Deconinck E, Rohrlich PS

Eur J Haematol. 2012 Mar;88(3):269-72

CD304 is preferentially expressed on a subset of B-lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry.

Solly F, Angelot F, Garand R, Ferrand C, Seillès E, Schillinger F, Decobecq A, Billot M, Larosa F, Plouvier E, Deconinck E, Legrand F, Saas P, Rohrlich PS, Garnache-Ottou F

Cytometry A. 2012 Jan;81(1):17-24

The COX-2 gene promoter polymorphism -765 delays CD4 T-cell reconstitution after lymphocyte depletion with antithymocyte globulins.

Courivaud C, Bamoulid J, Ferrand C, Tiberghien P, Chalopin JM, Saas P, Ducloux D

Hum Immunol. 2011 Nov;72(11):1060-3

A multiplex SNaPshot assay as a rapid method for detecting KRAS and BRAF mutations in advanced colorectal cancers.

Magnin S, Viel E, Baraquin A, Valmary-Degano S, Kantelip B, Pretet JL, Mougin C, Bigand M, Girardo B, Borg C, Ferrand C

J Mol Diagn. 2011 Sep;13(5):485-92

Successful mobilization and engraftment of PBSCs derived from donor cord blood cells after a previous allogeneic RIC single unrelated cord blood transplantation.

Larosa F, Deconinck E, Helias P, Fontan J, Heczko M, Brion A, Ledu K, Delaby P, Vuiller J, Ferrand C, Saas P, Pouthier F, Dormoy A, Chabod J, Malugani C, Rohrlich PS, Legrand F

Blood. 2011 Jul 14;118(2):476-8.

Thymic function, anti-thymocytes globulins, and cancer after renal transplantation.

Ducloux D, Bamoulid J, Courivaud C, Gaugler B, Rebibou JM, Ferrand C, Chalopin JM, Borg C, Tiberghien P, Saas P

Transpl Immunol. 2011 Jul;25(1):56-60

Early immune reconstitution and efficient graft vs tumor effect after unrelated partially matched double cord blood transplantation in refractory 8p11 syndrome.

Larosa F, Maddens S, Legrand F, Pouthier F, Ferrand C, Saas P, Hayette S, Chabod J, Tiberghien P, Rohrlich PS, Deconinck E

Bone Marrow Transplant. 2011 Apr;46(4):622-4

Novel role for STAT3 in transcriptional regulation of NK immune cell targeting receptor MICA on cancer cells.

Bedel R, Thiery-Vuillemin A, Grandclement C, Balland J, Remy-Martin JP, Kantelip B, Pallandre JR, Pivot X, Ferrand C, Tiberghien P, Borg C

Cancer Res. 2011 Mar 1;71(5):1615-26

Neuropilin-2 expression promotes TGF-beta1-mediated epithelial to mesenchymal transition in colorectal cancer cells.

Grandclement C, Pallandre JR, Valmary Degano S, Viel E, Bouard A, Balland J, Remy-Martin JP, Simon B, Rouleau A, Boireau W, Klagsbrun M, Ferrand C, Borg C

PLoS One. 2011;6(7):e20444

Influence of cyclooxygenase-2 (COX-2) gene promoter polymorphism at position -765 on skin cancer after renal transplantation.

Aubin F, Courivaud C, Bamoulid J, Loupy A, Deschamps M, Ferrand C, Le Corre D, Tiberghien P, Chalopin JM, Legendre C, Thervet E, Humbert P, Saas P, Ducloux D

J Invest Dermatol. 2010 Aug;130(8):2134-6

Identification of an alternative CD20 transcript variant in B-cell malignancies coding for a novel protein associated to rituximab resistance.

Henry C, Deschamps M, Rohrlich PS, Pallandre JR, Remy-Martin JP, Callanan M, Traverse-Glehen A, GrandClement C, Garnache-Ottou F, Gressin R, Deconinck E, Salles G, Robinet E, Tiberghien P, Borg C, Ferrand C

Blood. 2010 Mar 25;115(12):2420-9

Influence of cyclooxygenase-2 (COX-2) gene promoter polymorphism -765 on graft loss after renal transplantation.

Courivaud C, Bamoulid J, Loupy A, Deschamps M, Ferrand C, Le Corre D, Tiberghien P, Chalopin JM, Legendre C, Thervet E, Saas P, Ducloux D

Am J Transplant. 2009 Dec;9(12):2752-7

Evidence of premature immune aging in patients thymectomized during early childhood.

Sauce D, Larsen M, Fastenackels S, Duperrier A, Keller M, Grubeck-Loebenstein B, Ferrand C, Debre P, Sidi D, Appay V

J Clin Invest. 2009 Oct;119(10):3070-8

Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia.

Garnache-Ottou F, Feuillard J, Ferrand C, Biichle S, Trimoreau F, Seilles E, Salaun V, Garand R, Lepelley P, Maynadie M, Kuhlein E, Deconinck E, Daliphard S, Chaperot L, Beseggio L, Foisseaud V, Macintyre E, Bene MC, Saas P, Jacob MC

Br J Haematol. 2009 Jun;145(5):624-36

Regulatory T-cell expansion and function do not account for the impaired alloreactivity of ex vivo-expanded T cells.

Montcuquet N, Mercier-Letondal P, Perruche S, Duperrier A, Couturier M, Bouchekioua A, Bonyhadi M, Ferrand C, Tiberghien P, Robinet E

Immunology. 2008 Nov;125(3):320-30

Early immune response against retrovirally transduced herpes simplex virus thymidine kinase-expressing gene-modified T cells coinfused with a T cell-depleted marrow graft: an altered immune response?

Mercier-Letondal P, Deschamps M, Sauce D, Certoux JM, Milpied N, Lioure B, Cahn JY, Deconinck E, Ferrand C, Tiberghien P, Robinet E

Hum Gene Ther. 2008 Sep;19(9):937-50.

Immune constitution monitoring after PBMC transplantation in complete DiGeorge syndrome: an eight-year follow-up.

Daguindau N, Decot V, Nzietchueng R, Ferrand C, Picard C, Latger-Cannard V, Gregoire MJ, Beri M, Salmon A, Stoltz JF, Bordigoni P, Bensoussan D

Clin Immunol. 2008 Aug;128(2):164-71

Abnormal expression of only the CD34 part of a transgenic CD34/herpes simplex virus-thymidine kinase fusion protein is associated with ganciclovir resistance.

Bennour E, Ferrand C, Remy-Martin JP, Certoux JM, Gorke S, Qasim W, Gaspar HB, Baumert T, Duperrier A, Deschamps M, Fehse B, Tiberghien P, Robinet E

Hum Gene Ther. 2008 Jul;19(7):699-709.

Alloreactivity of ex vivo-expanded T cells is correlated with expansion and CD4/CD8 ratio.

Mercier-Letondal P, Montcuquet N, Sauce D, Certoux JM, Jeanningros S, Ferrand C, Bonyhadi M, Tiberghien P, Robinet E

Cytotherapy. 2008;10(3):275-88.

Deletions within the HSV-tk transgene in long-lasting circulating gene-modified T cells infused with a hematopoietic graft.

Deschamps M, Mercier-Lethondal P, Certoux JM, Henry C, Lioure B, Pagneux C, Cahn JY, Deconinck E, Robinet E, Tiberghien P, Ferrand C

Blood. 2007 Dec 1;110(12):3842-52

Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes.

Audia S, Nicolas A, Cathelin D, Larmonier N, Ferrand C, Foucher P, Fanton A, Bergoin E, Maynadie M, Arnould L, Bateman A, Lorcerie B, Solary E, Chauffert B, Bonnotte B

Clin Exp Immunol. 2007 Dec;150(3):523-30

Immune modulation and microchimerism after unmodified versus leukoreduced allogeneic red blood cell transfusion in cancer patients: results of a randomized study.

Lapierre V, Auperin A, Robinet E, Ferrand C, Oubouzar N, Tramalloni D, Saas P, Debaene B, Lasser P, Tiberghien P

Transfusion. 2007 Sep;47(9):1691-9.

B7-1 and 4-1BB ligand expression on a myeloma cell line makes it possible to expand autologous tumor-specific cytotoxic T cells in vitro.

Lu ZY, Condomines M, Tarte K, Nadal L, Delteil MC, Rossi JF, Ferrand C, Klein B

Exp Hematol. 2007 Mar;35(3):443-53.

Isolation of regulatory T cells in the skin of a human hand-allograft, up to six years posttransplantation.

Eljaafari A, Badet L, Kanitakis J, Ferrand C, Farre A, Petruzzo P, Morelon E, Dubosson M, Tiberghien P, Dubois V, Martin X, Miossec P, Dubernard JM

Transplantation. 2006 Dec 27;82(12):1764-8.

Standardized analysis for the quantification of Vbeta CDR3 T-cell receptor diversity.

Long SA, Khalili J, Ashe J, Berenson R, Ferrand C, Bonyhadi M

J Immunol Methods. 2006 Dec 20;317(1-2):100-13

Urinary cytotoxic molecular markers for a noninvasive diagnosis in acute renal transplant rejection.

Yannaraki M, Rebibou JM, Ducloux D, Saas P, Duperrier A, Felix S, Rifle G, Chalopin JM, Herve P, Tiberghien P, Ferrand C

Transpl Int. 2006 Sep;19(9):759-68.

A single sub-erythematous exposure of solar-simulated radiation on the elicitation phase of contact hypersensitivity induces IL-10-producing T-regulatory cells in human skin.

Stoebner PE, Rahmoun M, Ferrand C, Meunier L, Yssel H, Pene J

Exp Dermatol. 2006 Aug;15(8):615-24.

IL-6 promoter polymorphism -174 is associated with new-onset diabetes after transplantation.

Bamoulid J, Courivaud C, Deschamps M, Mercier P, Ferrand C, Penfornis A, Tiberghien P, Chalopin JM, Saas P, Ducloux D

J Am Soc Nephrol. 2006 Aug;17(8):2333-40

Selection of Epstein-Barr virus specific cytotoxic T lymphocytes can be performed with B lymphoblastoid cell lines created in serum-free media.

Gallot G, Vollant S, Vivien R, Clemenceau B, Ferrand C, Tiberghien P, Gaschet J, Robillard N, Vie H

Clin Exp Immunol. 2006 Apr;144(1):158-68.

T cell repertoire and Epstein-Barr virus-specific T cell response in chronic active Epstein-Barr virus infection: a case study.

Gallot G, Hamidou MA, Clemenceau B, Gaschet J, Tiberghien P, Ferrand C, Vivien R, Barbarot S, Coste-Burel M, Moreau A, Vie H

Clin Immunol. 2006 Apr;119(1):79-86

Intravenous apoptotic spleen cell infusion induces a TGF-beta-dependent regulatory T-cell expansion.

Kleinclauss F, Perruche S, Masson E, de Carvalho Bittencourt M, Biichle S, Remy-Martin JP, Ferrand C, Martin M, Bittard H, Chalopin JM, Seilles E, Tiberghien P, Saas P

Cell Death Differ. 2006 Jan;13(1):41-52.

Intrathymic administration of hematopoietic progenitor cells enhances T cell reconstitution in ZAP-70 severe combined immunodeficiency.

Adjali O, Vicente RR, Ferrand C, Jacquet C, Mongellaz C, Tiberghien P, Chebli K, Zimmermann VS, Taylor N

Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13586-91

Induction of tissue factor expression on human umbilical vein endothelial cells by cell-specific HLA class I antibody: preliminary data.

Naji A, Deschaseaux F, Racadot E, Ferrand C, Justrabo E, Guignier F, Mousson C, Rifle G

Transplant Proc. 2005 Jul-Aug;37(6):2892-3.

Relevance of Toll-like receptor-4 polymorphisms in renal transplantation.

Ducloux D, Deschamps M, Yannaraki M, Ferrand C, Bamoulid J, Saas P, Kazory A, Chalopin JM, Tiberghien P

Kidney Int. 2005 Jun;67(6):2454-61.

Peripheral T-cell expansion and low infection rate after reduced-intensity conditioning and allogeneic blood stem cell transplantation.

Larosa F, Marmier C, Robinet E, Ferrand C, Saas P, Deconinck E, Bulabois CE, Rohrlich PS, Ledu K, Helias P, Tiberghien P, Cahn JY

Bone Marrow Transplant. 2005 May;35(9):859-68.

Relative quantification of residual tumor cells by lightcycler real-time IgH PCR in autografted multiple myeloma patients.

Rimelen V, Ferrand C, Debecker A, Sovalat H, Tancredi C, Eidenschenk A, Henon P

Leukemia. 2005 Mar;19(3):492-5.

Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells.

Garnache-Ottou F, Chaperot L, Biichle S, Ferrand C, Remy-Martin JP, Deconinck E, de Tailly PD, Bulabois B, Poulet J, Kuhlein E, Jacob MC, Salaun V, Arock M, Drenou B, Schillinger F, Seilles E, Tiberghien P, Bensa JC, Plumas J, Saas P

Blood. 2005 Feb 1;105(3):1256-64